Skip to content
Peptigraph home

Tesamorelin Dosage: Doses Studied, Units and Chart

What doses of Tesamorelin have been used in published research, how they convert to syringe units, and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGHRH analogUpdated
Doses studied
12 studies
with a stated dose, listed below
Frequency
Varies by study
as used in studies
Half-life
11 minutes
subcutaneous (EGRIFTA WR 1.28 mg), in people · FDA label (Egrifta WR)
Vial sizes sold
2 mg, 5 mg, 10 mg, 20 mg

Dosing on the FDA label

Quoted from the approved product label. It applies to the approved product used as prescribed, not to compounded or research-chemical versions.

Doses used in published studies

Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.

Doses of Tesamorelin used in published studies
DoseFrequency and routeStudy typeSource
1 mg tesamorelinnot stated · not stated · 10 weeksHuman controlled trialn = 22eNeurologicalSci 2026, PMID 42382101
2 mg tesamorelinonce daily · subcutaneous (once daily, per abstract) · 12 months, then 6-month open-label phaseHuman RCTn = 61The lancet. HIV 2019, PMID 31611038
tesamorelin (dose not stated)not stated · not stated · 26 weeksHuman RCTThe Journal of frailty & aging 2019, PMID 31237318
1 or 2 mgdaily · subcutaneous · 14 consecutive daysHuman RCTn = 38Clinical pharmacokinetics 2015, PMID 25358450
tesamorelin (dose not stated in abstract)daily · subcutaneous (per trials) · 26 and 52 weeksHuman RCTClinical infectious diseases 2012, PMID 22495074
2 mg tesamorelinonce daily · subcutaneous (not stated in abstract) · 12 monthsHuman RCTn = 60The Journal of clinical endocrinology and metabolism 2012, PMID 23015655
1 mg/d tesamorelindaily before bedtime · subcutaneous · 20 weeksHuman RCTn = 152Archives of neurology 2012, PMID 22869065
2 mg tesamorelinevery day · subcutaneous · 6 months, then 12 months totalHuman RCTn = 404Journal of acquired immune deficiency syndromes 2010, PMID 20101189
2 mg tesamorelindaily · subcutaneous · 52 weeksHuman RCTn = 410AIDS 2008, PMID 18690162
2 mg tesamorelindaily · subcutaneous · 26 weeksHuman RCTn = 412The New England journal of medicine 2007, PMID 18057338
1 or 2 mgonce daily · subcutaneous · 12 weeksHuman RCTn = 61AIDS 2005, PMID 16052083
tesamorelin 2 mgdaily · subcutaneous (per trials) · not statedMeta-analysisn = 909Journal of the International Association of Providers of AIDS Care 2026, PMID 42538058

Dose to syringe units

For a 10 mg vial mixed with 2 mL of bacteriostatic water (5 mg/mL), on a U-100 syringe. These are reference amounts for the math, not suggested doses.

0.5 mg
10 u
1 mg
20 u
1.5 mg
30 u
2 mg
40 u
2.5 mg
50 u
3 mg
60 u
Use your own vial and water

Before anyone considers it

  • Tesamorelin is FDA approved (Egrifta); research-chemical versions are not the approved drug.
  • Compounded and research-chemical versions are not the approved product and are not checked by the FDA for identity, purity or dose.
  • Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
  • People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.

Common questions

How many units is 1.5 mg of Tesamorelin?

It depends on the water added. A 10 mg vial with 2 mL of water gives 5 mg/mL, so 1.5 mg is 30 units on a U-100 syringe. Use the calculator for other mixes.

Is Tesamorelin FDA approved?

Tesamorelin is FDA approved (Egrifta). Products sold as research chemicals are not the approved drug and are not checked by the FDA.

More on Tesamorelin

Side effectsWhat labels and studies report, and what is unknown.CalculatorVial, water and dose to syringe units.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.How to injectSites, syringe types and hygiene, step by step.

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  4. 4EGRIFTA SV (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta SV), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  5. 5The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
  6. 6Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
  7. 7The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
  8. 8Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.Clinical pharmacokinetics · 2015PMID 25358450Accessed 2 Oct 2026
  9. 9Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012PMID 22495074Accessed 2 Oct 2026
  10. 10Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.The Journal of clinical endocrinology and metabolism · 2012PMID 23015655Accessed 2 Oct 2026
  11. 11Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.Archives of neurology · 2012PMID 22869065Accessed 2 Oct 2026
  12. 12Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.Journal of acquired immune deficiency syndromes (1999) · 2010PMID 20101189Accessed 2 Oct 2026
  13. 13Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.AIDS (London, England) · 2008PMID 18690162Accessed 2 Oct 2026
  14. 14Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
  15. 15A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.AIDS (London, England) · 2005PMID 16052083Accessed 2 Oct 2026
  16. 16Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.Journal of the International Association of Providers of AIDS Care · 2026PMID 42538058Accessed 2 Oct 2026

Found an error? Report a correction.